These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24277511)

  • 1. PET-CT in oncological patients: analysis of informal care costs in cost-benefit assessment.
    Orlacchio A; Ciarrapico AM; Schillaci O; Chegai F; Tosti D; D'Alba F; Guazzaroni M; Simonetti G
    Radiol Med; 2014 Apr; 119(4):283-9. PubMed ID: 24277511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/CT and contrast enhanced CT in single vs. two separate sessions: a cost analysis study.
    Picchio M; Mansueto M; Crivellaro C; Guerra L; Marcelli S; Arosio M; Sironi S; Gianolli L; Grimaldi A; Messa C
    Q J Nucl Med Mol Imaging; 2012 Jun; 56(3):309-16. PubMed ID: 22510702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of PET and PET/computed tomography: a systematic review.
    Gerke O; Hermansson R; Hess S; Schifter S; Vach W; Høilund-Carlsen PF
    PET Clin; 2015 Jan; 10(1):105-24. PubMed ID: 25455883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission.
    Huntington SF; Svoboda J; Doshi JA
    J Clin Oncol; 2015 May; 33(13):1467-74. PubMed ID: 25823735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison.
    Mansueto M; Grimaldi A; Torbica A; Pepe G; Giovacchini G; Messa C; Fazio F
    Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):224-34. PubMed ID: 17538525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of cost-effectiveness in the diagnosis of fever of unknown origin and the role of (18)F-FDG PET-CT: a proposal of diagnostic algorithm].
    Becerra Nakayo EM; García Vicente AM; Soriano Castrejón AM; Mendoza Narváez JA; Talavera Rubio MP; Poblete García VM; Cordero García JM
    Rev Esp Med Nucl Imagen Mol; 2012; 31(4):178-86. PubMed ID: 23067686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of 18F-FDG PET/CT in detecting suspected recurrence or metastasis in well-differentiated thyroid carcinoma patients with negative diagnostic total body scan in Thailand: a decision analysis.
    Khiewvan B; Nopmaneejumruslers C; Pusuwan P; Tuchinda P; Tojinda N; Ubolnuch K
    J Med Assoc Thai; 2013 Oct; 96(10):1350-64. PubMed ID: 24350419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach.
    Vriens D; Adang EM; Netea-Maier RT; Smit JW; de Wilt JH; Oyen WJ; de Geus-Oei LF
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3263-74. PubMed ID: 24873995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.
    Smyth E; Schöder H; Strong VE; Capanu M; Kelsen DP; Coit DG; Shah MA
    Cancer; 2012 Nov; 118(22):5481-8. PubMed ID: 22549558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [18FDG-PET/CT cost-effectiveness compared to CT at the end of treatment in pediatric Hodgkin's lymphoma patients].
    García-Molina M; Chicaíza-Becerra L; Moreno-Calderon A; Prieto-Martínez V; Sarmiento-Urbina I; Linares-Ballesteros A
    Rev Salud Publica (Bogota); 2014; 16(2):260-9. PubMed ID: 25383499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours.
    Schreiter NF; Brenner W; Nogami M; Buchert R; Huppertz A; Pape UF; Prasad V; Hamm B; Maurer MH
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):72-82. PubMed ID: 21927931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum carcinoembryonic antigen measurement, abdominal contrast-enhanced computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of colorectal cancer recurrence: a correlative study.
    Ozkan E; Soydal C; Araz M; Aras G
    Nucl Med Commun; 2012 Sep; 33(9):990-4. PubMed ID: 22842225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
    van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
    J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ¹⁸F-FDG PET/CT in inflammation of unknown origin: a cost-effectiveness pilot-study.
    Balink H; Tan SS; Veeger NJ; Holleman F; van Eck-Smit BL; Bennink RJ; Verberne HJ
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1408-13. PubMed ID: 25655485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism.
    Rondina MT; Wanner N; Pendleton RC; Kraiss LW; Vinik R; Zimmerman GA; Heilbrun M; Hoffman JM; Morton KA
    Thromb Res; 2012 Jan; 129(1):22-7. PubMed ID: 21802118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
    Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
    Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis of PET and contrast enhanced CT better than the numbers?
    Kendi AT; Corey A; Magliocca KR; Nickleach DC; Galt J; Switchenko JM; El-Deiry MW; Wadsworth JT; Hudgins PA; Saba NF; Schuster DM
    Eur J Radiol; 2015 Jun; 84(6):1171-6. PubMed ID: 25816993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of FDG-PET on radiation therapy: economic results of a STIC study].
    Remonnay R; Morelle M; Giammarile F; Pommier P; Carrère MO
    Cancer Radiother; 2009 Jul; 13(4):313-7. PubMed ID: 19493691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analysis of FDG-PET-guided management of the neck after primary chemoradiotherapy for node-positive head and neck squamous cell carcinoma.
    Pryor DI; Porceddu SV; Scuffham PA; Whitty JA; Thomas PA; Burmeister BH
    Head Neck; 2013 Sep; 35(9):1287-94. PubMed ID: 22987817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of 18F-FDG PET/CT and contrast-enhanced CT.
    Schramm N; Rominger A; Schmidt C; Morelli JN; Schmid-Tannwald C; Meinel FG; Reiser MF; Rist C
    Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1014-24. PubMed ID: 23503574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.